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Background. Multidrug-resistant Plasmodium falciparum is a major threat to global malaria control. Parasites
develop resistance by gradually acquiring genetic polymorphisms that decrease drug susceptibility. The aim of this
study was to investigate the extent to which parasites with different genetic characteristics are able to withstand
individual drug blood concentrations.
Methods. We analyzed 2 clinical trials that assessed the efﬁcacy and effectiveness of artemether-lumefantrine.
As a proof of concept, we used measured day 7 lumefantrine concentrations to estimate the concentrations at
which reinfections multiplied. P. falciparum multidrug resistance gene 1 (pfmdr1) genotypes of these parasites
were then correlated to drug susceptibility.
Results. Reinfecting parasites with the pfmdr1 N86/184F/D1246 haplotype were able to withstand lumefan-
trine blood concentrations 15-fold higher than those with the 86Y/Y184/1246Y haplotype.
Conclusions. By estimating drug concentrations, we were able to quantify the contribution of pfmdr1 single-
nucleotide polymorphisms to reduced lumefantrine susceptibility. The method can be applied to all long–half-life
antimalarial drugs, enables early detection of P. falciparum with reduced drug susceptibility in vivo, and represents
a novel way for unveiling molecular markers of antimalarial drug resistance.
Keywords. Plasmodium falciparum; malaria; pfmdr1; lumefantrine; artemether-lumefantrine; antimalarials;
pharmacokinetics; drug resistance; in vivo.
The evolution and spread of artemisinin-based
combination therapy (ACT)–resistant Plasmodium fal-
ciparum may have drastic consequences on global
malaria control and elimination efforts. Development
of ACT resistance is likely to start with a decreased
efﬁcacy of the long–half-life partner drug, gradually
transforming ACT into an unprotected artemisinin-
derivativemonotherapy.Thisnotionunderlies theWorld
Health Organization policy that artemisinin-derivative
agents should be exclusively used in combination with
other drugs for the treatment of uncomplicated malaria
and never together with a failing drug.
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In high-transmission areas, the development of resistance
against long–half-life partner drugs is likely to occur through
the posttreatment selection of less sensitive parasites, as rein-
fections are exposed to subtherapeutic blood levels of these
slowly eliminated drugs. The posttreatment selection of drug
resistance–associated single-nucleotide polymorphisms (SNPs)
observed after both artemether-lumefantrine [1–3] and
artesunate-amodiaquine [4, 5] treatment, involving polymor-
phisms of the P. falciparum multidrug resistance gene 1
(pfmdr1; National Center for Biotechnology Information Ref-
erence Sequence gene ID 813045), are examples of this.
To identify useful surveillance tools such as genetic markers
of resistance against the long-acting partners in ACT, a clear
deﬁnition of the P. falciparum resistance phenotype is needed.
Unfortunately, in vivo resistance has been difﬁcult to deﬁne
with precision. Treatment failure can be due to nonparasito-
logical factors like poor patient drug bioavailability or adher-
ence. Furthermore, the use of biodiversity markers such as
P. falciparum merozoite surface protein 1 (pfmsp1), pfmsp2, and
glutamate-rich protein (glurp) to distinguish between recrudes-
cence (treatment failure) and reinfections may be less reliable
than previously expected [6, 7]. As for ﬁeld in vitro methods,
these are only applicable to subsets of infections with appropri-
ate parasitemia and tend to select for high-ﬁtness parasites. We
propose a complementary concept for deﬁning molecular
markers of in vivo P. falciparum susceptibility.
In recent years, we have witnessed important technological
developments in the determination of drug levels in blood,
using samples collected on ﬁlter papers. The increased robust-
ness of these techniques has allowed routine analysis of drug
levels of the ACT partner drugs on the seventh day (D7) after
treatment initiation as a surrogate marker for drug exposure
(ie, area under the concentration-time curve [AUC]) [8].
Long-acting antimalarial drugs (eg, lumefantrine [LUM]) are
in their terminal elimination phase at D7 and have a log-
linear decrease of drug concentrations [8]. This enables later
drug levels to be inferred using the measured D7 concentra-
tion and the terminal elimination half-life. The accuracy of the
inferred drug concentrations depends on knowledge of the
pharmacokinetic characteristics of the target group, especially
the terminal elimination rate constant. Estimated drug con-
centrations can then be correlated to genotypes (SNPs, copy
number variation) of recurrent parasites.
As a proof of concept, we correlated polymorphisms in
pfmdr1 with estimated LUM drug concentrations in patients
treated with artemether-lumefantrine.
METHODS
Clinical Trials
The infections analyzed in this report came from 2 arte-
mether-lumefantrine clinical efﬁcacy/effectiveness trials. Full
details of these studies have been reported previously and are
summarized in brief in Table 1 [9, 10].
Study I was a randomized 2-arm artemether-lumefantrine
(AL) clinical trial (efﬁcacy vs effectiveness) among 359 febrile
patients <5 years of age (age range, 3–59 months) in the Bag-
amoyo district of Tanzania [9] (ClinicalTrials.gov identiﬁer
ISRCTN69189899). All patients had conﬁrmed P. falciparum
parasitemia (2000–200 000 asexual parasites/μL) on admission
and were followed weekly for 56 days. For the 161 patients
with recurrent infection, a second AL treatment was given,
and the patient was followed weekly for an additional 42 days.
Study II was a single-arm effectiveness study of the standard
6 dose AL regimen involving 244 subjects from rural Kibaha,
Ngeta, and Mwanabwito districts, Tanzania (ClinicalTrials.gov
identiﬁer NCT00454961) [10]. Inclusion criteria were identical
to those described for study I, with the exception of including
individuals with a parasite load of <2000 asexual parasites/μL.
The patients were followed weekly for 42 days. For both studies,
capillary blood samples were taken at enrollment (D0), at the
weekly clinical assessment, and in the event of recurrent para-
sitemia (R0) and preserved on 3-mm ﬁlter paper.
Patients with polymerase chain reaction (PCR)–conﬁrmed
reinfections at D7 and onward, with LUM ﬁlter paper samples
collected on D7 and concentrations successfully measured (see
below), were included in the present work. Recrudescences
were excluded because they, by deﬁnition, have survived treat-
ment with both artemether and LUM. Recrudescent infections
therefore represent a different population of parasites. Addi-
tional details regarding the patient population are speciﬁed in
Table 1. Before enrollment, written informed consent was pro-
vided by parents or guardians. Both studies were approved by
Table 1. Description of the Study Populations
Variable
Study 1
(n = 359)
Study 2
(n = 244)
Overall
(n = 603)
Reinfection, no. of
subjects
170 84 254
Recrudescence, no. of
subjects
7 10 17
pfmdr1 N86 day 0, %
of subjects (pure
N86/total)a
43 (155/357) 49 (115/234) 46 (270/591)
pfmdr1 N86 reinfection,
% of subjects (pure
N86/total)
61 (101/166) 79 (65/82) 67 (166/248)
Time to reinfection, d,
median (95% CI)b
35 (34–36) 28 (25–31) 32 (30–34)
Abbreviations: CI, confidence interval; pfmdr1, Plasmodium falciparum
multidrug resistance gene 1.
a The present single-nucleotide polymorphism discrimination has been
previously published [9, 10].
b The difference in time to reinfection is partly explained by the different
follow-up durations in study 1 (56 days) and study 2 (42 days)
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the National Institute for Medical Research, Tanzania, and the
Regional Ethics Committee, Stockholm, Sweden.
Quantiﬁcation of LUM Concentrations at D7
Seven days after treatment initiation (D7), capillary blood
samples were applied on ﬁlter papers pretreated with 0.75 M
tartaric acid and were stored at −20°C. LUM whole-blood
concentrations were measured by solid-phase extraction and
liquid chromatography, as described elsewhere [11]. A total of
530 capillary samples were quantiﬁed and 34 excluded because
measurements were below the limit of detection (100 nM).
The within-study assay performance showed a precision (coef-
ﬁcient of variation [CV]) of 6.07%–11.5%.
Estimation of LUM Concentrations After D7
LUM elimination is in the log-linear phase after D7, and indi-
vidual drug concentrations can be extrapolated to the point of
interest according to the individual pharmacokinetic charac-
teristics. Population estimates were derived from a detailed
pharmacokinetic study previously performed in the same
setting [12]. The population mean of the terminal elimination
half-life used in this work was 80 hours. This was in close
agreement with previously published data [13].
The expected drug concentrations on the day of hepatocyte
burst were calculated for all patients with reinfections (Equa-
tion 1). The estimated day of hepatocyte burst was assumed to
occur 7 days before microscopy-based detection of recurrent
parasitemia during follow up after AL treatment. This method
permitted an in vivo estimate of the reinfecting parasite’s
ability to multiply under drug pressure.
CEST ¼ CD7  eðktÞ ð1Þ
where CEST is the estimated LUM blood concentration, CD7 is
the individually measured D7 LUM blood concentration (in
nanomoles), k is the terminal elimination rate constant set to
0.00865 hours−1 [6], and t is the time in hours from D7 to
estimated hepatocyte burst.
Data Transformation
Price et al previously deﬁned a venous plasma LUM cutoff
concentration of 331 nM (175 ng/mL) to predict recrudes-
cence (treatment failure) with 75% sensitivity and 84% specif-
icity [14]. We converted this value to capillary blood samples,
taking into account the hematocrit for our study population,
and got an equivalent LUM cutoff concentration of 328 nM
(Supplementary Material). Thus, LUM concentrations >328 nM
at D7 are deﬁned here as the threshold of exposure of the par-
asites to an adequate AUC.
Molecular Analysis
The pfmdr1 N86Y status of every recurrent parasitemia (R0,
initial day of microscopy-determined recurrent parasitemia),
previously determined through PCR–restriction fragment
length polymorphism analysis [9, 10], was reanalyzed and con-
ﬁrmed through reampliﬁcation and direct PCR amplicon se-
quencing. The pfmdr1 Y184F and D1246Y SNPs were
analyzed by PCR amplicon sequencing. One patient, who ex-
perienced a second recurrent infection, with estimated LUM
blood concentrations of >550 nM, was also added to the anal-
ysis. The PCR success rates for analysis of codon 86, 184, and
1246 were 97% (259 of 267), 92% (245 of 267), and 90% (241
of 267), respectively. The presence of pfmdr1 copy number
variation, previously associated with in vivo artemether-lume-
fantrine response [14, 15], has been previously tested [9], with
only 1 infection identiﬁed as carrying 2 copies (86Y). Reinfec-
tions and recrudescences were distinguished using previously
published stepwise genotyping of pfmsp2, followed by pfmsp1
and glurp [9, 10]. For primer sequences, see Supplementary
Table 1.
Statistical Analysis
The statistical analyses were done using Stata v.12 and Sigma-
Plot 11. Statistical signiﬁcance was deﬁned as a P value
of < .05. The 95% conﬁdence intervals were computed in
STATA v.12, for binomial variables, and by SigmaPlot 11, for
survival data. Normally distributed continuous data were ana-
lyzed with the Student t test. A Mann–Whitney rank sum test
was used to compare estimated LUM blood concentrations for
different genotypes. Mixed infections with the presence of
both alleles were excluded from analysis. Only pure infections
were analyzed for pfmdr1 haplotypes, and rare haplotypes
present in <3 infections were excluded.
RESULTS
Reinfecting parasites carrying pfmdr1 N86, 184F, or D1246
pure alleles were able to survive at signiﬁcantly higher median
estimated LUM blood concentrations, compared with parasites
harboring their alternative alleles (Figure 1 and Table 2). The
largest difference was observed for the N86Y SNP, with con-
centrations of 25.4 nM versus 2.08 nM (a 12.2-fold difference)
between the N- and the Y-carrying parasites. For pfmdr1
Y184F and D1246Y, the corresponding differences were 4.09
nM versus 34.5 nM (an 8.4-fold difference) and 15.9 nM
versus 3.23 nM (a 4.9-fold difference), respectively.
P. falciparum with the N86/184F/D1246 haplotype was stat-
istically signiﬁcantly less sensitive than P. falciparum with the
alternative haplotypes 86Y/Y184/1246Y (31.4 nM vs 2.16 nM
[a 14.5-fold difference]; P < .001) and 86Y/Y184/D1246 (31.4
nM vs 0.678 nM [a 46.3-fold difference]; P < .001; Figure 2
and Table 2). There was no signiﬁcant correlation between
pfmdr1 haplotypes and D0 parasitemia (as a proxy marker of
ﬁtness)
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The highest estimated LUM concentration that reinfecting
parasites carrying N86 versus those carrying 86Y could with-
stand differed by a factor of 35 (1184.3 nM and 34.3 nM,
respectively; Figure 1). The inﬂuence of Y184F and D1246Y
SNPs on drug susceptibility is less clear-cut, with the “sensi-
tive” Y184 and 1246Y parasites able to withstand the highest
drug levels (1184.3 nM and 1081.5 nM, respectively.
There was a distinct subset of 8 parasites that were able to
grow at estimated LUM concentrations of >550 nM, whereas
no other parasites grew at concentrations >300 nM (Table 3).
The subset represented 4.57% (8 of 175; 95% conﬁdence inter-
val, 1.99%–8.81%) of the reinfections occurring up to 35 days
after treatment initiation. These least susceptible parasites all
carried the pfmdr1 N86 allele and had LUM D7 levels 1.8–
10.3-fold higher than 328 nM, conﬁrming adequate treatment
and bioavailability.
There were no signiﬁcant differences in D7 concentration
between patients who were reinfected with one of these “least
susceptible parasites” and those who were adequately treated
and then experienced recrudescence (P = .113; Supplementary
Table 2).
DISCUSSION
The present study allowed an estimate of in vivo susceptibility
to LUM by P. falciparum and its association with pfmdr1
alleles. The data provide evidence that the observed post-AL
treatment selection of pfmdr1 alleles is associated with a
signiﬁcant decrease in LUM susceptibility. This reinforces the
hypothesis that pfmdr1 is a central player in P. falciparum
resistance to LUM.
Table 2. Estimated Median Lumefantrine (LUM) Blood
Concentrations for Different Plasmodium falciparum Multidrug
Resistance Gene 1 (pfmdr1) Single-Nucleotide Polymorphisms
(SNPs) and Haplotypes
pfmdr1 No.
LUM
CEST,
nM
Interquartile
Range P
SNP
N86 166 25.4 3.85–72.7 < .001
86Y 37 2.08 0.248–4.43
184F 80 34.5 10.5–87.5 < .001
Y184 127 4.09 0.879–25.4
D1246 195 15.9 2.26–46.4 .006
1246Y 23 3.23 0.293–10.9
Haplotype
NFD 64 31.4 10.5–76.1
NYD 63 15.8 2.53–46 .045
YYY 15 2.16 0.293–3.77 ≤ .001
YYD 15 0.678 0.108–3.87 ≤ .001
Abbreviation: CEST, estimated LUM concentration.
Combinations of pfmdr1 polymorphisms at codon N86Y, Y184F, D1246Y.
Mann–Whitney rank sum test was used to compare estimated lumefantrine
concentrations between SNPs and the NFD haplotype against other
haplotypes.
Figure 1. Estimated lumefantrine (LUM) concentrations for reinfecting
Plasmodium falciparum carrying different pfmdr1 single-nucleotide poly-
morphisms (SNPs) at codons 86, 184, and 1246. Each reinfection is rep-
resented 3 times, once for each SNP. Only pure infections (concerning
the pfmdr1 SNPs) were included in the analysis. According to the Mann–
Whitney rank sum test, there was a signiﬁcant difference between N86
and 86Y (P < .001), 184F and Y184 (P < .001), and D1246 and 1246Y
(P = .006; Table 2). Black lines, median values; grey lines, interquartile
ranges.
Figure 2. Estimated lumefantrine concentrations for reinfecting Plas-
modium falciparum carrying different pfmdr1 haplotypes at codons 86,
184, and 1246. Each open circle represents a reinfection. Only haplotypes
with ≥3 observations were considered for analysis. Median values were
31.4 nM (interquartile range [IQR], 10.5–76.1 nM) for NFD, 15.8 nM (IQR,
2.53–46.0 nM) for NYD, 2.16 nM (IQR, 0.293–3.77 nM) for YYY, and
0.678 nM (IQR, 0.108–3.87 nM) for YYD (Table 2). Black lines, median
values; grey lines, interquartile ranges.
Genotype and Drug Level Associations • JID 2013:207 (1 March) • 845
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/207/5/842/1078282 by B-O
n C
onsortium
 Portugal user on 13 M
arch 2019
We found that pfmdr1 N86, 184F, and 1246D were associat-
ed with reduced LUM susceptibility, compared with the alter-
native 86Y, Y184, and Y1246 alleles. When analyzed as
haplotypes, the NFD haplotype were able to withstand esti-
mated LUM concentration 15-fold higher than those with the
YYY haplotype. This is in line with previous in vivo and in
vitro work [1, 2, 16]. Clinical isolates from Kenya with pfmdr1
N86 had a 2.9-fold higher median LUM median inhibitory
concentration than the 86Y allele in vitro [16]. In line with the
Kenyan results, we found a 12.2-fold difference between these
2 SNPs in vivo. Haplotype analysis showed a trend of de-
creased LUM susceptibility, in the order of NFD, NYD, YYY,
and YYD. This suggests a gradually acquired tolerance, start-
ing with N86, followed by the combination of N86 + D1246
and, thereafter, the combination of N86 + 184F + D1246. This
might be comparable with the selection of SNPs in P. falcipa-
rum dihydrofolate reductase (pfdhfr) associated with a stepwise
decrease in susceptibility to sulfadoxine-pyrimethamine [17].
The D0 parasitemias were similar irrespective of haplotype,
supporting the hypothesis that differences in drug tolerability
is a measure of reduced drug susceptibility as opposed to
ﬁtness.
An important question is whether we have identiﬁed LUM-
resistant parasites. We identiﬁed P. falciparum parasites able
to survive at levels near or above blood drug concentrations of
1 µM. Such capacity to withstand drug pressure means that
these parasites are able to start proliferating just 2 days after
completion of the AL treatment, when the LUM blood levels
drop to these levels [18]. Irrespective of exact concentrations,
taking into account sampling errors, such a collapse of protec-
tion capacity is probably paving the way for the emergence of
fully resistant parasites (if they are not already present). This
is in agreement with a previously proposed model describing
AL-driven pfmdr1 SNP selection in Africa [18]: the parasite is
developing its way of “climbing” the pharmacokinetic curve.
As discussed above, the N86 allele seems to be fundamental
to—albeit not sufﬁcient for—this process, to which other
pfmdr1 SNPs (184F and D1246) and additional, as-yet-
unveiled genetic changes add.
The proposed in vivo genotype/phenotype association
method has the advantage of being independent of constraints
associated with the deﬁnitions of recrudescence and clinical
failure [6, 19], drug bioavailability, and other issues not di-
rectly related to parasitological drug sensitivity. The method
provides an in vivo estimate of the capacity of parasites to
evade drug action. It has an in-built high speciﬁcity, since no
sensitive parasites are expected to be detected at high blood
drug levels. This high speciﬁcity is expected to be an impor-
tant factor for the unambiguous identiﬁcation of tolerant/re-
sistant P. falciparum. The method will underestimate the
proportion of parasites with reduced drug susceptibility,
because such parasites, as well as fully susceptible parasites,
will thrive when drug concentrations are low. The method will
thereby be prone to false-negative ﬁndings. Further meta-anal-
ysis of clinical trials using this method will increase the possi-
bility to reliable identify resistant parasites and resistance-
associated SNPs.
In this work, we have beneﬁted from a previous detailed
pharmacokinetic study performed in the same area on a
similar study population [12]. This provided the necessary
data for inferring LUM concentrations beyond D7. Such phar-
macokinetic data from the speciﬁc target populations is gener-
ally not available in malaria settings. We suggest that for the
application of the proposed concept, future ACT efﬁcacy/effec-
tiveness trials should preferably include at least 2 drug level
assessment points (eg, at D7 and D14), thereby deﬁning an
individual slope of drug elimination for each patient. This
would overcome the limitation in this study of using the mean
population terminal elimination half-life rather than individu-
al values to extrapolate individual D7 levels to the time of
hepatocyte burst. Because of the pharmacokinetics of LUM,
we expect a signiﬁcant number of patients to show quantiﬁ-
able concentrations of this antimalarial 2 weeks after treat-
ment initiation [20]. Additionally, recent developments in
liquid chromatography–mass spectrometry [21] promise im-
provements of least 1 order of magnitude (ie, down to 1–10
nM) in lower limits of detection. This will make the determi-
nation of the D14 LUM concentrations feasible in a large ma-
jority of patients.
Our proof of concept was applied to artemether-lumefan-
trine clinical trials. This method is, however, equally valuable
for studying emerging resistance toward all ACT long-acting
partner drugs. The use of drug concentrations can help in ac-
curate interpretation of clinical trial outcomes and will also
Table 3. Reinfecting Plasmodium falciparum Able to Grow at
Estimated Lumefantrine (LUM) Concentrations of >550 nM
Parasite
Code Study
LUM
CEST, nM
LUM
CD7, nM
pfmdr1
N86Y
pfmdr1
Y184F
pfmdr1
D1246Y
F147 I 1184 1184 N Y D
11129 II 1081 1081 N F Y
F26 I 706 1070 N F D
F63 I 678 678 … … D
11066 II 581 581 N Y D
9096 II 794 3397 N F …
F202 I 565 2416 N Y D
F13 I 558 2388 N F D
Polymorphisms in pfmdr1 at codon N86Y, Y184F, and D1246Y were analyzed
on the day of recurrent parasitaemia.
Abbreviations: CD7, measured LUM concentration 7 days after treatment
initiation; CEST, estimated LUM concentrations; D, aspartic acid; F,
phenylalanine; N, asparagine; Y, tyrosine; –, unsuccessful polymerase chain
reaction analysis.
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give an improved deﬁnition of the phenotype associated with
reduced susceptibility. The concept can also be used to identi-
fy genotypes associated with reduced susceptibility to Plasmo-
dium vivax, where ex vivo/in vitro work is limited.
In conclusion, we present a new concept using D7 drug con-
centrations and pharmacokinetic data to estimate the drug con-
centrations that parasites withstand in vivo. We found that
reinfecting parasites with the pfmdr1 N86/184F/D1246 haplo-
type were able to withstand LUM blood concentrations 15-fold
higher than parasites with the pfmdr1 86Y/Y184/1246Y, sup-
porting the role of pfmdr1 in LUM susceptibility. Our method
to correlate drug concentrations and genotypes is applicable to
all antimalarial drugs, can contribute to the early detection of
reduced drug susceptibility, and represents a novel way for un-
veiling molecular markers of antimalarial drug resistance.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org/). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages
regarding errors should be addressed to the author.
Notes
Acknowledgments. This report is dedicated to the late Niklas Linde-
gårdh. This work was only possible because of his key role in the develop-
ment of methods for determination of drug levels in ﬁlter-paper-preserved
blood samples. His comments on the present report were highly valuable.
Financial support. This work was supported by the Swedish Develop-
ment Cooperation Agency-Department for Research Cooperation (SIDA-
SAREC; SWE 2004–3850, Bil-Tz 16/9875007059 and SWE-2009-165),
the World Health Organization MIM-TDR (protocol ID: [A60100] MAL
IRM 06 03), the Goljes Foundation, and the Swedish medical research
council (K2010-56X-21457-01-3). The Mahidol-Oxford Tropical Medicine
Research Unit is supported by the Wellcome Trust of Great Britain.
Potential conﬂicts of interest. All authors: No reported conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed
References
1. Sisowath C, Stromberg J, Martensson A, et al. In vivo selection of
Plasmodium falciparum pfmdr1 86N coding alleles by artemether-
lumefantrine (Coartem). J Infect Dis 2005; 191:1014–7.
2. Sisowath C, Ferreira PE, Bustamante LY, et al. The role of pfmdr1 in
Plasmodium falciparum tolerance to artemether-lumefantrine in
Africa. Trop Med Int Health 2007; 12:736–42.
3. Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of Plasmodi-
um falciparum parasites carrying the chloroquine-susceptible pfcrt
K76 allele after treatment with artemether-lumefantrine in Africa.
J Infect Dis 2009; 199:750–7.
4. Holmgren G, Hamrin J, Svard J, Martensson A, Gil JP, Bjorkman A.
Selection of pfmdr1 mutations after amodiaquine monotherapy and
amodiaquine plus artemisinin combination therapy in East Africa. In-
fection, Genetics and Evolution : Infect Genet Evol 2007; 7:562–9.
5. Humphreys GS, Merinopoulos I, Ahmed J, et al. Amodiaquine and
artemether-lumefantrine select distinct alleles of the Plasmodium fal-
ciparum mdr1 gene in Tanzanian children treated for uncomplicated
malaria. Antimicrob Agents Chemother 2007; 51:991–7.
6. Martensson A, Ngasala B, Ursing J, et al. Inﬂuence of consecutive-day
blood sampling on polymerase chain reaction-adjusted parasitological
cure rates in an antimalarial-drug trial conducted in Tanzania. J Infect
Dis 2007; 195:597–601.
7. Juliano JJ, Ariey F, Sem R, et al. Misclassiﬁcation of drug failure in
Plasmodium falciparum clinical trials in southeast Asia. J Infect Dis
2009; 200:624–8.
8. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J. Simpliﬁed
antimalarial therapeutic monitoring: using the day-7 drug level?
Trends Parasitol 2008; 24:159–63.
9. Ngasala BE, Malmberg M, Carlsson AM, et al. Efﬁcacy and effective-
ness of artemether-lumefantrine after initial and repeated treatment in
children <5 years of age with acute uncomplicated Plasmodium falcip-
arum malaria in rural Tanzania: a randomized trial. Clin Infect Dis
2011; 52:873–82.
10. Ngasala BE, Malmberg M, Carlsson AM, et al. Effectiveness of arte-
mether-lumefantrine provided by community health workers in
under-ﬁve children with uncomplicated malaria in rural Tanzania: an
open label prospective study. Malar J 2011; 10:64.
11. Blessborn D, Romsing S, Annerberg A, et al. Development and valida-
tion of an automated solid-phase extraction and liquid chromato-
graphic method for determination of lumefantrine in capillary blood
on sampling paper. J Pharm Biomed Anal 2007; 45:282–7.
12. Hietala SF, Martensson A, Ngasala B, et al. Population pharmacoki-
netics and pharmacodynamics of artemether and lumefantrine
during combination treatment in children with uncomplicated fal-
ciparum malaria in Tanzania. Antimicrob Agents Chemother 2010;
54:4780–8.
13. Tarning J, McGready R, Lindegardh N, et al. Population pharmacoki-
netics of lumefantrine in pregnant women treated with artemether-lu-
mefantrine for uncomplicated Plasmodium falciparum malaria.
Antimicrob Agents Chemother 2009; 53:3837–46.
14. Price RN, Uhlemann AC, van Vugt M, et al. Molecular and pharma-
cological determinants of the therapeutic response to artemether-
lumefantrine in multidrug-resistant Plasmodium falciparum malaria.
Clin Infect Dis 2006; 42:1570–7.
15. Gadalla NB, Adam I, Elzaki SE, et al. Increased pfmdr1 copy number
and sequence polymorphisms in Plasmodium falciparum isolates from
Sudanese malaria patients treated with artemether-lumefantrine. Anti-
microb Agents Chemother 2011; 55:5408–11.
16. Mwai L, Kiara SM, Abdirahman A, et al. In vitro activities of pipera-
quine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium
falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimi-
crob Agents Chemother 2009; 53:5069–73.
17. Mita T, Tanabe K, Kita K. Spread and evolution of Plasmodium falcip-
arum drug resistance. Parasitol Int 2009; 58:201–9.
18. Hastings IM, Ward SA. Coartem (artemether-lumefantrine) in Africa:
the beginning of the end? J Infect Dis 2005; 192:1303–4; author reply
4–5.
19. Carlsson AM, Ngasala BE, Dahlstrom S, et al. Plasmodium falciparum
population dynamics during the early phase of anti-malarial drug
treatment in Tanzanian children with acute uncomplicated malaria.
Malar J 2011; 10:380.
20. Djimde AA, Tekete M, Abdulla S, et al. Pharmacokinetic and pharma-
codynamic characteristics of a new pediatric formulation of arte-
mether-lumefantrine in African children with uncomplicated
Plasmodium falciparum malaria. Antimicrob Agents Chemother 2011;
55:3994–9.
21. Domanski D, Percy AJ, Yang J, et al. MRM-based multiplexed quanti-
tation of 67 putative cardiovascular disease biomarkers in human
plasma. Proteomics 2012; 12:1222–43.
Genotype and Drug Level Associations • JID 2013:207 (1 March) • 847
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/207/5/842/1078282 by B-O
n C
onsortium
 Portugal user on 13 M
arch 2019
